Buscador de ensayos clínicos

Comentarios

Only for patients with metastatic BRAF V600E mutant colorectal cancer. Must have been previously treated with one or two treatment regimens.

ZN-c3: azenosertib; experimental Wee1 inhibitor. Oral.

Encorafenib: small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway (Braftovi®). Oral.

Cetuximab: (Erbitux®) epidermal growth factor receptor (EGFR) inhibitor. Intravenous.

Enlaces útiles

Criterios de inclusión

Criterios de inclusión:

* Histologically or cytologically confirmed metastatic Stage IV colorectal adenocarcinoma.
* Documented evidence of a BRAF V600E mutation in tumor tissue or blood
* Presence of measurable disease per RECIST version 1.1 guidelines.
* Disease progression after 1 or 2 previous systemic regimens for metastatic disease
* Adequate bone marrow function
* Adequate hepatic and renal function

Criterios de exclusión

Criterios de exclusión:

* Documented clinical disease progression or radiographic disease progression during the screening period
* Leptomeningeal disease.
* Symptomatic brain metastasis.
* Presence of acute or chronic pancreatitis.
* Unable to swallow, retain, and absorb oral medications.
* Clinically significant cardiovascular diseases
* Evidence of active noninfectious pneumonitis.
* Evidence of active and uncontrolled bacterial or viral infection, within 2 weeks prior to start of any of the study interventions
* Participants with known positivity for HIV
* Active hepatitis B or hepatitis C infection
* Concurrent or previous other malignancy within 2 years of study entry
* Has had an allogeneic tissue/solid organ transplant
* Pregnant or females of childbearing potential who have a positive β-hCG laboratory test result within 14 days prior to enrollment or is breastfeeding